Great Lakes Advisors LLC Makes New $1.59 Million Investment in Enovis Corporation $ENOV

Great Lakes Advisors LLC acquired a new stake in Enovis Corporation (NYSE:ENOV) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 76,726 shares of the company’s stock, valued at approximately $1,588,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Arax Advisory Partners bought a new stake in shares of Enovis in the fourth quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the period. Danske Bank A S bought a new stake in shares of Enovis in the 3rd quarter worth approximately $64,000. iSAM Funds UK Ltd bought a new stake in shares of Enovis in the 3rd quarter worth approximately $80,000. Finally, Brown Brothers Harriman & Co. purchased a new position in shares of Enovis during the third quarter valued at approximately $90,000. 98.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

ENOV has been the topic of several recent analyst reports. Canaccord Genuity Group cut their price target on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group reiterated a “buy” rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Finally, Wells Fargo & Company lowered their price objective on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.29.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of Enovis stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders acquired 4,200 shares of company stock worth $92,084 in the last ninety days. 2.90% of the stock is owned by company insiders.

Enovis Trading Up 0.2%

NYSE:ENOV opened at $26.22 on Friday. The firm has a market capitalization of $1.51 billion, a P/E ratio of -1.36 and a beta of 1.34. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. Enovis Corporation has a one year low of $19.14 and a one year high of $34.28. The company’s 50-day simple moving average is $25.22 and its 200 day simple moving average is $24.15.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. The company had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts forecast that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.